Ergotamine is an alpha-1 selective adrenergic agonist vasoconstrictor used to treat migraines with or without aura and cluster headaches. A vasoconstrictor found in ergot of Central Europe.
- Mechanism
- Curator reviewed
Ergotamine acts on migraine by one of two proposed mechanisms: 1) activation of 5-HT1D receptors located on intracranial blood vessels, including those on arterio-venous anastomoses, leads to vasoconstriction, which correlates with the relief of migraine headache, and 2) activation of 5-HT1D receptors on sensory nerve endings of the trigeminal system results in the inhibition of pro-inflammatory neuropeptide release.
- Primary indication
- For use as therapy to abort or prevent vascular headache, e.g., migraine, migraine variants, or so called "histaminic cephalalgia".Curator reviewed · 9 structured indications
- Formula / weight
- C33H35N5O5 · 581.6615 g/mol (avg)
- First approval
- Canada, 1997 · United States, 1953
- Brand names
Resolves to
XCGSFFUVFURLIX-VFGNJEKYSA-NSMILES[H][C@@]12CCCN1C(=O)[C@H](CC1=CC=CC=C1)N1C(=O)[C@](C)(NC(=O)[C@H]3CN(C)[C@]4([H])CC5=CNC6=CC=CC(=C56)C4=C3)O[C@@]21OWhat you can answer from here — as of October 01, 2026
Which drugs share a target with Ergotamine, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account